Updates, Insights & Perspectives

Executive Summary Artificial intelligence (AI) has rapidly transitioned from an experimental tool to a core driver of modern drug development. In the specific domain of reformulation and repurposing — where developers aim to unlock new therapeutic potential from validated pharmacology — AI is proving especially transformative. By integrating data across chemistry, biology, clinical outcomes, and real-world evidence, AI systems can identify promising new indications, optimize

Executive Summary Glioblastoma (GBM) and many central nervous system (CNS) disorders remain among the most challenging conditions to treat, largely due to the inability of many therapeutics to cross the blood–brain barrier (BBB). As a result, researchers and clinicians have increasingly turned their attention toward nose-to-brain delivery — an approach that uses the unique anatomy of the nasal cavity to bypass the BBB and deliver therapeutics directly to the brain. This artic

Executive Summary Stereotactic ablative radiotherapy (SABR) for early stage non–small cell lung cancer (NSCLC) and concurrent chemoradiation (CRT) for unresectable Stage III disease have become essential therapeutic backbones. SABR delivers highly focused, ablative radiation in a few fractions, while CRT provides integrated local and systemic treatment over several weeks. Both approaches are effective but constrained by persistent local progression, distant relapse, and treat

Executive Summary Non–small cell lung cancer (NSCLC) is shaped not only by the genetic characteristics of cancer cells but also by the complex environment surrounding them. This “tumor microenvironment” — consisting of stromal tissue, immune cells, vasculature, metabolic conditions, and oxygen availability — plays a major role in determining how tumors respond to radiotherapy. This article provides a high-level, non-technical overview of the key features of the NSCLC microenv

Executive Summary Lung cancer care has evolved significantly over the past two decades, with major advances in radiotherapy, immunotherapy, and targeted systemic treatments. Yet real-world challenges remain. Many patients struggle with the cumulative burden of systemic therapy, and a large proportion of the NSCLC population cannot tolerate aggressive regimens due to age, comorbidities, or overall frailty. As oncology increasingly shifts toward precision, patient-centered care

Executive Summary Radiotherapy remains a cornerstone of lung cancer treatment, yet meaningful innovation in enhancing its effectiveness has been slow to emerge. Radiosensitization — the concept of improving how tumors respond to radiation — has long been recognized as a promising avenue, but real-world progress has been limited by historical challenges in tolerability, specificity, and clinical development. This article provides a high-level overview of why radiosensitization